Advertisement

Topics

AXIM Biotech Announces the Production of CanChew Plus™, the Next Generation Controlled Release CBD Chewing Gum

19:00 EST 28 Feb 2017 | Globe Newswire

NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, began production of CanChew Plus™, the next generation of the company’s award-winning controlled-release cannabidiol (CBD) functional chewing gum.

CanChew® is the world’s first patented controlled-release cannabinoid chewing gum containing 50 mg of hemp oil and 10 mg of CBD.

CanChew Plus™ contains the same active ingredients and is designed to be 60% smaller than the original CanChew® gums for an improved chewing experience. Most importantly, CanChew Plus™ features a new and improved oral mucosal delivery system through microencapsulation that increases the bioavailability of the active ingredient from less than 50% after chewing for two hours with the prior version of the gum to 80% absorption rate of CBD in just 30 minutes of chewing.

In its natural form, cannabinoids are lipophilic, not water-soluble and tend to stick to the chewing gum matrix, therefore diminishing effective release into the bloodstream. Microencapsulation renders cannabinoids soluble and dramatically increases the bioavailability of CBD, while bypassing the first-pass hepatic metabolism.

“We are excited to introduce the new and improved version of our popular controlled release CBD chewing gum. With patented microencapsulation technologies, the new products will offer higher absorption rate and more predictable delivery of our hemp oil extracted CBD. As we move forward with various clinical trials, we remain committed to bringing better cannabinoid based nutraceutical product to consumers,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech.

CanChew Plus™ is a unique industrial hemp based chewing gum that is distinctly different and superior to any other brands of gum on the market. Features listed on the CanChew website include:

  • Non-habit forming
  • No prescription needed
  • Available in all 50 states
  • Great-tasting mint gum has no artificial sweeteners or preservatives
  • Non-GMO, gluten free, vegan and kosher

Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLiving Foundation and honored with its Triple Leaf Award.

About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabinoid-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™ a CBD-based controlled release chewing gum. A clinical trial with a CanChew Plus™ containing 50 mg of CBD will enter a clinical trial in patients with IBS (irritable bowel syndrome), and MedChew Rx, a combination CBD/THC gum that will be undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
andrew.hard@cmwmedia.com
P. +1888 829-0070
www.cmwmedia.com

Investor Relations Contact
Shiwei Yin, Grayling
Shiwei.Yin@grayling.com
P. +1646 284-9474
Lucia Domville, Grayling
lucia.domville@grayling.com
P. +1646 284-9416

Corporate Contact Info
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "AXIM Biotech Announces the Production of CanChew Plus™, the Next Generation Controlled Release CBD Chewing Gum"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...